NCT03176472: A reported trial by Regenacy Pharmaceuticals LLC
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03176472 |
|---|---|
| Title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 7, 2020 |
| Completion date | Oct. 31, 2022 |
| Required reporting date | Oct. 31, 2023, midnight |
| Actual reporting date | May 30, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |